This grant offers support for studies aimed at achieving a more comprehensive understanding of the intricate interactions between the immune system and the central nervous system (CNS) in individuals living with HIV. The focus is specifically on people who are currently receiving Anti-Retroviral therapy (ART). Successful proposals are anticipated to employ a combination of in-vitro (laboratory-based cell and tissue cultures) and in-vivo (whole organism or animal models) systems to thoroughly investigate these critical biological processes. The overarching purpose of this funding opportunity is to significantly advance scientific knowledge concerning neuro-immune dynamics in the context of HIV infection, ultimately contributing to the development of better therapeutic approaches and improved quality of life for affected patients.
Opportunity ID: 335355
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-MH-21-251 |
| Funding Opportunity Title: | Deciphering Immune-CNS interactions in HIV utilizing in-vitro and in-vivo model systems (R21 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 19, 2021 |
| Last Updated Date: | Aug 19, 2021 |
| Original Closing Date for Applications: | Dec 07, 2021 |
| Current Closing Date for Applications: | Dec 07, 2021 |
| Archive Date: | Jan 12, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments For profit organizations other than small businesses State governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Public and State controlled institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This initiative is to support studies to better comprehend Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-251.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270327 | Nov 16, 2021 | Dec 07, 2021 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00268651 | Nov 07, 2021 | Jan 24, 2022 | View |
Package 1
Mandatory forms
335355 RR_SF424_5_0-5.0.pdf
335355 PHS398_CoverPageSupplement_5_0-5.0.pdf
335355 RR_OtherProjectInfo_1_4-1.4.pdf
335355 PerformanceSite_4_0-4.0.pdf
335355 RR_KeyPersonExpanded_4_0-4.0.pdf
335355 PHS398_ResearchPlan_4_0-4.0.pdf
335355 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335355 RR_Budget_3_0-3.0.pdf
335355 RR_SubawardBudget30_3_0-3.0.pdf
335355 PHS398_ModularBudget_1_2-1.2.pdf
335355 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335355 RR_SF424_2_0-2.0.pdf
335355 PHS398_CoverPageSupplement_5_0-5.0.pdf
335355 RR_OtherProjectInfo_1_4-1.4.pdf
335355 PerformanceSite_2_0-2.0.pdf
335355 RR_KeyPersonExpanded_2_0-2.0.pdf
335355 PHS398_ResearchPlan_4_0-4.0.pdf
335355 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335355 RR_Budget_1_4-1.4.pdf
335355 RR_SubawardBudget30_1_4-1.4.pdf
335355 PHS398_ModularBudget_1_2-1.2.pdf
335355 PHS_AssignmentRequestForm_3_0-3.0.pdf